# Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study

> **NCT07297602** · PHASE2 · RECRUITING · sponsor: **Nora Mohamed Abdelrazik** · enrollment: 36 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** Oral roflumilast

## Key facts

- **NCT ID:** NCT07297602
- **Lead sponsor:** Nora Mohamed Abdelrazik
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2026-05-20
- **Final completion:** 2026-05-20
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-12-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07297602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07297602, "Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients Aged 12 Years and Older: A Pilot Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07297602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*